Cargando…

Extending in Silico Protein Target Prediction Models to Include Functional Effects

In silico protein target deconvolution is frequently used for mechanism-of-action investigations; however existing protocols usually do not predict compound functional effects, such as activation or inhibition, upon binding to their protein counterparts. This study is hence concerned with including...

Descripción completa

Detalles Bibliográficos
Autores principales: Mervin, Lewis H., Afzal, Avid M., Brive, Lars, Engkvist, Ola, Bender, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004408/
https://www.ncbi.nlm.nih.gov/pubmed/29942259
http://dx.doi.org/10.3389/fphar.2018.00613
_version_ 1783332517095407616
author Mervin, Lewis H.
Afzal, Avid M.
Brive, Lars
Engkvist, Ola
Bender, Andreas
author_facet Mervin, Lewis H.
Afzal, Avid M.
Brive, Lars
Engkvist, Ola
Bender, Andreas
author_sort Mervin, Lewis H.
collection PubMed
description In silico protein target deconvolution is frequently used for mechanism-of-action investigations; however existing protocols usually do not predict compound functional effects, such as activation or inhibition, upon binding to their protein counterparts. This study is hence concerned with including functional effects in target prediction. To this end, we assimilated a bioactivity training set for 332 targets, comprising 817,239 active data points with unknown functional effect (binding data) and 20,761,260 inactive compounds, along with 226,045 activating and 1,032,439 inhibiting data points from functional screens. Chemical space analysis of the data first showed some separation between compound sets (binding and inhibiting compounds were more similar to each other than both binding and activating or activating and inhibiting compounds), providing a rationale for implementing functional prediction models. We employed three different architectures to predict functional response, ranging from simplistic random forest models (‘Arch1’) to cascaded models which use separate binding and functional effect classification steps (‘Arch2’ and ‘Arch3’), differing in the way training sets were generated. Fivefold stratified cross-validation outlined cascading predictions provides superior precision and recall based on an internal test set. We next prospectively validated the architectures using a temporal set of 153,467 of in-house data points (after a 4-month interim from initial data extraction). Results outlined Arch3 performed with the highest target class averaged precision and recall scores of 71% and 53%, which we attribute to the use of inactive background sets. Distance-based applicability domain (AD) analysis outlined that Arch3 provides superior extrapolation into novel areas of chemical space, and thus based on the results presented here, propose as the most suitable architecture for the functional effect prediction of small molecules. We finally conclude including functional effects could provide vital insight in future studies, to annotate cases of unanticipated functional changeover, as outlined by our CHRM1 case study.
format Online
Article
Text
id pubmed-6004408
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60044082018-06-25 Extending in Silico Protein Target Prediction Models to Include Functional Effects Mervin, Lewis H. Afzal, Avid M. Brive, Lars Engkvist, Ola Bender, Andreas Front Pharmacol Pharmacology In silico protein target deconvolution is frequently used for mechanism-of-action investigations; however existing protocols usually do not predict compound functional effects, such as activation or inhibition, upon binding to their protein counterparts. This study is hence concerned with including functional effects in target prediction. To this end, we assimilated a bioactivity training set for 332 targets, comprising 817,239 active data points with unknown functional effect (binding data) and 20,761,260 inactive compounds, along with 226,045 activating and 1,032,439 inhibiting data points from functional screens. Chemical space analysis of the data first showed some separation between compound sets (binding and inhibiting compounds were more similar to each other than both binding and activating or activating and inhibiting compounds), providing a rationale for implementing functional prediction models. We employed three different architectures to predict functional response, ranging from simplistic random forest models (‘Arch1’) to cascaded models which use separate binding and functional effect classification steps (‘Arch2’ and ‘Arch3’), differing in the way training sets were generated. Fivefold stratified cross-validation outlined cascading predictions provides superior precision and recall based on an internal test set. We next prospectively validated the architectures using a temporal set of 153,467 of in-house data points (after a 4-month interim from initial data extraction). Results outlined Arch3 performed with the highest target class averaged precision and recall scores of 71% and 53%, which we attribute to the use of inactive background sets. Distance-based applicability domain (AD) analysis outlined that Arch3 provides superior extrapolation into novel areas of chemical space, and thus based on the results presented here, propose as the most suitable architecture for the functional effect prediction of small molecules. We finally conclude including functional effects could provide vital insight in future studies, to annotate cases of unanticipated functional changeover, as outlined by our CHRM1 case study. Frontiers Media S.A. 2018-06-11 /pmc/articles/PMC6004408/ /pubmed/29942259 http://dx.doi.org/10.3389/fphar.2018.00613 Text en Copyright © 2018 Mervin, Afzal, Brive, Engkvist and Bender. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mervin, Lewis H.
Afzal, Avid M.
Brive, Lars
Engkvist, Ola
Bender, Andreas
Extending in Silico Protein Target Prediction Models to Include Functional Effects
title Extending in Silico Protein Target Prediction Models to Include Functional Effects
title_full Extending in Silico Protein Target Prediction Models to Include Functional Effects
title_fullStr Extending in Silico Protein Target Prediction Models to Include Functional Effects
title_full_unstemmed Extending in Silico Protein Target Prediction Models to Include Functional Effects
title_short Extending in Silico Protein Target Prediction Models to Include Functional Effects
title_sort extending in silico protein target prediction models to include functional effects
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004408/
https://www.ncbi.nlm.nih.gov/pubmed/29942259
http://dx.doi.org/10.3389/fphar.2018.00613
work_keys_str_mv AT mervinlewish extendinginsilicoproteintargetpredictionmodelstoincludefunctionaleffects
AT afzalavidm extendinginsilicoproteintargetpredictionmodelstoincludefunctionaleffects
AT brivelars extendinginsilicoproteintargetpredictionmodelstoincludefunctionaleffects
AT engkvistola extendinginsilicoproteintargetpredictionmodelstoincludefunctionaleffects
AT benderandreas extendinginsilicoproteintargetpredictionmodelstoincludefunctionaleffects